Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is involved in developing tamper-proof opioids which prevent both drug abuse and overdoses. Ensysce Biosciences, formerly known as Leisure Acquisition Corp., is based in SAN DIEGO.
| Revenue (Most Recent Fiscal Year) | $5.21M |
| Net Income (Most Recent Fiscal Year) | $-7.99M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.53 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -244.50% |
| Net Margin (Trailing 12 Months) | -244.47% |
| Return on Equity (Trailing 12 Months) | -437.31% |
| Return on Assets (Trailing 12 Months) | -231.45% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.29 |
| Earnings per Share (Most Recent Fiscal Year) | $-11.45 |
| Diluted Earnings per Share (Trailing 12 Months) | $-6.37 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.63M |
| Free Float | 3.35M |
| Market Capitalization | $5.92M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 1.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 5.63% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |